Celecoxib as an Adjuvant to Fluvoxamine in Moderate to Severe Obsessive-compulsive Disorder: A Double-blind, Placebo-controlled, Randomized Trial-Reference-Cited by-同舟云学术

Celecoxib as an Adjuvant to Fluvoxamine in Moderate to Severe Obsessive-compulsive Disorder: A Double-blind, Placebo-controlled, Randomized Trial

Published:2015-05-06 Issue:04/05 Volume:48 Page:136-140
ISSN:0176-3679
Container-title:Pharmacopsychiatry
language:en
Short-container-title:Pharmacopsychiatry

Author:

Shalbafan M.¹,Mohammadinejad P.²,Shariat S.-V.³,Alavi K.³,Zeinoddini A.²,Salehi M.⁴,Askari N.²,Akhondzadeh S.²

Affiliation:

1. School of Medicine, Iran University of Medical Sciences, Tehran, Iran

2. Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran

3. Mental Health Research Center, Tehran Institute of Psychiatry, School of Behavioral Sciences and Mental Health, Iran University of Medical Sciences, Tehran, Iran

4. Tehran Institute of Psychiatry, School of Behavioral Sciences and Mental Health, Iran University of Medical Sciences, Tehran, Iran

Publisher

Georg Thieme Verlag KG

Subject

Pharmacology (medical),Psychiatry and Mental health,General Medicine

Link

http://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0035-1549929.pdf

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hereditary Patterns and Genetic Associations in Obsessive-Compulsive Disorder (OCD): Neuropsychiatric Insights, Genetic Influences, and Treatment Perspectives;Current Gene Therapy;2024-08-30

2. Pharmakotherapie;S3-Leitlinie Zwangsstörungen;2024

3. Efficacy and safety of 5-hydroxytryptamine-3 (5-HT3) receptor antagonists in augmentation with selective serotonin reuptake inhibitors (SSRIs) in the treatment of moderate to severe obsessive–compulsive disorder: a systematic review and meta-analysis of randomized clinical trials;Scientific Reports;2023-11-27

4. Agomelatine augmentation of sertraline in the treatment of moderate to severe obsessive-compulsive disorder: a randomized double-blinded placebo-controlled clinical trial;BMC Psychiatry;2023-09-21

5. Challenges and Opportunities for Celecoxib Repurposing;Pharmaceutical Research;2023-08-08